Kingdon Capital Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Kingdon Capital Management’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-398,169	Closed	-$2.38M	–	77
2019 Q3	$2.38M	Buy	398,169 +219,716	+123%	+$2.25M	0.28%	54
2019 Q2	$2.23M	Hold	178,453	–	–	0.22%	61
2019 Q1	$2.28M	Buy	+178,453	New	+$2.4M	0.31%	51

Other funds holding MITO

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kingdon Capital Management's MITO Position: Q4 2019 in Review

Kingdon Capital Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2019, closing a stake of 398,169 shares — an estimated $2.38M sold.

Kingdon Capital Management first reported a position in MITO in Q1 2019 and held it in 3 quarters. The position peaked at $2.38M in Q3 2019. 5 funds tracked by Wall St. Rank hold MITO as of Q4 2019.

Kingdon Capital Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2019 after selling out during the quarter.
Kingdon Capital Management sold 398,169 Stealth BioTherapeutics Corp. ADS shares in Q4 2019, an estimated $2.38M.
Kingdon Capital Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2019 and held it in 3 quarters.
Kingdon Capital Management's Stealth BioTherapeutics Corp. ADS position peaked at $2.38M in Q3 2019.
5 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2019.

Based on Kingdon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.